Blinatumomab 是一种 CD3/CD19 定向双特异性 T 细胞接合剂，用于治疗复发或难治性 B 细胞前体急性淋巴细胞白血病 (BCP-ALL)。尽管blinatumomab已显示出疗效，但它可能引起严重的不良事件，包括细胞因子释放综合征和神经系统事件。在神经系统事件中，脑病很少见，而且缺乏相关知识。在此，我们介绍一例博纳吐单抗相关脑病的儿科病例，该病例最初表现为难治性惊厥，后来发展为脑梗塞。患者经历了长期瘫痪和脑损伤加重。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Blinatumomab is a CD3/CD19-directed bispecific T-cell engager used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although blinatumomab has shown efficacy, it can cause serious adverse events, including cytokine release syndrome and neurological events. Among the neurological events, encephalopathy is rare, and knowledge is lacking. Herein, we present a pediatric case of blinatumomab-associated encephalopathy that initially presented with refractory convulsions and later developed into a cerebral infarction. The patient experienced prolonged paralysis and increased brain damage.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.